CGMP Manufacturing

Resilience has assembled a world-class team to combine new biomanufacturing technologies with existing manufacturing capabilities for biologic products that will provide the US Government with the ability to rapidly respond to emerging disease threats and chemical, biologic, radiological and nuclear (CBRN) threats. This team is also utilized for our commercial business where we partner with customers to provide development and manufacturing services for a wide array of biologic products.

Our primary manufacturing goal is to rapidly produce bulk drug substance according to the highest standards of quality.

Resilience’s capabilities include cell and gene therapies, live viral vaccines and vectors, oncolytic viruses, and monoclonal antibodies. We have an integrated team of partners to support product/process development and manufacturing, from the stage of clinical development through the manufacturing of commercial supply. Our highly-experienced team provides expertise from preclinical development through final product licensure in all relevant biologics production platforms.

Resilience provides broad and flexible capabilities including:

  • Process Development/Optimization of Upstream, Downstream and Formulations
  • CGMP Manufacturing of Biologics Drug Substance and Drug Product
  • Analytical Development and Testing